

FINANCIAL TEAR SHEET

CORPORATE PROFILE

Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.

PRIMARY IR CONTACT

Investor Relations
Phone: 647-479-9825
E-mail: ir@aptose.com

STOCK PERFORMANCE

APTO (COMMON STOCK)

Exchange	TSX (Canadian Dollar)
Price	Can\$4.12
Change (%)	▼ 0.29 (6.58%)
Volume	27,014
52 Week Low	Can\$1.64
Market Cap	Can\$137,661,861
Rolling EPS	-0.73
PE Ratio	0
Shares Outstanding	33,413,073

Data as of July 20, 2018 3:59 p.m. ET



APTO (COMMON STOCK)

Exchange	NASDAQ CM (US Dollar)
Price	\$3.13
Change (%)	▼ 0.17 (5.15%)
Volume	150,413
52 Week Low	\$1.30
Market Cap	\$104,582,918
Rolling EPS	-0.57
PE Ratio	0
Shares Outstanding	33,413,073

Data as of July 20, 2018 4:00 p.m. ET



RECENT PRESS RELEASES & UPCOMING EVENTS

July 10, 2018

Aptose Biosciences and CrystalGenomics Announce Issuance of Japanese Patent for CG-806

July 9, 2018

Aptose Biosciences to Participate at the Oppenheimer & Co. Inc. Boston Oncology Insight Summit and 1x1 Day

June 29, 2018

FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers

There are currently no events scheduled.

SEC FILINGS

Filing Date	Form
July 10, 2018	CT ORDER
July 10, 2018	6-K
July 9, 2018	6-K
July 9, 2018	6-K

CORPORATE GOVERNANCE

William G. Rice, Ph.D.	Chairman, President & Chief Executive Officer
Daniel D. Von Hoff, M.D., F.A.C.P.	Senior Vice President, Medical Affairs
Stephen B. Howell, M.D.	Acting Chief Medical Officer
Gregory Chow	Senior Vice President, Chief Financial Officer
Ernest Kitt	Vice President, Development and Technical Operations

Data provided by Nasdaq. Minimum 15 minutes delayed.